511 related articles for article (PubMed ID: 27927642)
1. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
[TBL] [Abstract][Full Text] [Related]
2. Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.
Adriawan IR; Atschekzei F; Dittrich-Breiholz O; Garantziotis P; Hirsch S; Risser LM; Kosanke M; Schmidt RE; Witte T; Sogkas G
Ann Rheum Dis; 2022 Jan; 81(1):124-131. PubMed ID: 34583923
[TBL] [Abstract][Full Text] [Related]
3. Significant augmentation of regulatory T cell numbers occurs during the early neonatal period.
Hayakawa S; Ohno N; Okada S; Kobayashi M
Clin Exp Immunol; 2017 Nov; 190(2):268-279. PubMed ID: 28677152
[TBL] [Abstract][Full Text] [Related]
4. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis.
Samson M; Audia S; Janikashvili N; Ciudad M; Trad M; Fraszczak J; Ornetti P; Maillefert JF; Miossec P; Bonnotte B
Arthritis Rheum; 2012 Aug; 64(8):2499-503. PubMed ID: 22488116
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for the treatment of giant cell arteritis.
Schirmer M; Muratore F; Salvarani C
Expert Rev Clin Immunol; 2018 May; 14(5):339-349. PubMed ID: 29676602
[TBL] [Abstract][Full Text] [Related]
6. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis.
Samson M; Audia S; Fraszczak J; Trad M; Ornetti P; Lakomy D; Ciudad M; Leguy V; Berthier S; Vinit J; Manckoundia P; Maillefert JF; Besancenot JF; Aho-Glele S; Olsson NO; Lorcerie B; Guillevin L; Mouthon L; Saas P; Bateman A; Martin L; Janikashvili N; Larmonier N; Bonnotte B
Arthritis Rheum; 2012 Nov; 64(11):3788-98. PubMed ID: 22833233
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
Kikuchi J; Hashizume M; Kaneko Y; Yoshimoto K; Nishina N; Takeuchi T
Arthritis Res Ther; 2015 Jan; 17(1):10. PubMed ID: 25604867
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
Yoshifuji H
Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
[TBL] [Abstract][Full Text] [Related]
9. The balance between Foxp3 and Ror-γt expression in peripheral blood is altered by tocilizumab and abatacept in patients with rheumatoid arthritis.
Tada Y; Ono N; Suematsu R; Tashiro S; Sadanaga Y; Tokuda Y; Ono Y; Nakao Y; Maruyama A; Ohta A; Koarada S
BMC Musculoskelet Disord; 2016 Jul; 17():290. PubMed ID: 27421886
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
12. Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity.
Basdeo SA; Moran B; Cluxton D; Canavan M; McCormick J; Connolly M; Orr C; Mills KH; Veale DJ; Fearon U; Fletcher JM
J Immunol; 2015 Jul; 195(2):528-40. PubMed ID: 26062995
[TBL] [Abstract][Full Text] [Related]
13. IL-1R1 is expressed on both Helios(+) and Helios(-) FoxP3(+) CD4(+) T cells in the rheumatic joint.
Müller M; Herrath J; Malmström V
Clin Exp Immunol; 2015 Oct; 182(1):90-100. PubMed ID: 26076982
[TBL] [Abstract][Full Text] [Related]
14. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.
Espígol-Frigolé G; Corbera-Bellalta M; Planas-Rigol E; Lozano E; Segarra M; García-Martínez A; Prieto-González S; Hernández-Rodríguez J; Grau JM; Rahman MU; Cid MC
Ann Rheum Dis; 2013 Sep; 72(9):1481-7. PubMed ID: 22993227
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
[TBL] [Abstract][Full Text] [Related]
16. Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
Ostapchuk YO; Perfilyeva YV; Kustova EA; Urazalieva NT; Omarbaeva NA; Talaeva SG; Belyaev NN
Breast Cancer; 2018 Nov; 25(6):687-697. PubMed ID: 29797233
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab, an effective treatment for relapsing giant cell arteritis.
Oliveira F; Butendieck RR; Ginsburg WW; Parikh K; Abril A
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S76-8. PubMed ID: 24854376
[TBL] [Abstract][Full Text] [Related]
19. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
[TBL] [Abstract][Full Text] [Related]
20. [Proliferation of CD4+ CD25+ regulatory T cells of rat by different cytokines in vitro].
Wang ZH; Zhu JY; Li T; Leng XS
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):844-7. PubMed ID: 18756991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
